News | Embolic Protection Devices | October 31, 2017

Distal Filter Embolic Protection Decreases No-reflow Phenomenon in ACS Patients With Attenuated Plaque

Primary endpoint occurred in more than 25 percent of DP patients versus more than 40 percent of patients randomized to conventional treatment

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.


October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the incidence of no-reflow phenomenon after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with attenuated plaque ≥5mm based upon intravascular imaging. It also examined its long-term effects.

Researchers enrolled 200 ACS patients who had a native coronary artery lesion and attenuated plaque with a longitudinal length of ≥5mm by pre-PCI IVUS. They were randomized to distal filter protection (DP) or conventional treatment (CT).

The primary endpoint of no-reflow phenomenon occurred in 26.5 percent in the DP group (N=98) and 41.7 percent in the CT group (N=96, P=0.0261) and the corrected TIMI frame count after revascularization was significantly lower in the DP group (23 vs. 30.5, P=0.0003). In addition, the incidence of in hospital adverse cardiac events was significantly lower in the DP group than in the CT group (0 percent vs. 5.2 percent, P=0.028).

“The selective use of embolic protection devices for patients at high risk for distal embolization is of great interest among interventional cardiologists,” said Kiyoshi Hibi, M.D., associate professor at Yokohama City University Medical Center in Yokohama, Japan. “VAMPIRE 3 shows that the use of distal embolic protection using a filter device decreased the incidence of no-reflow phenomenon with fewer serious adverse cardiac events after revascularization.”

The VAMPIRE 3 study was funded by Boston Scientific Corp., Nipro and Japan Lifeline. Hibi reported no disclosures.

For more information: www.tctconference.com

Related TCT Content

TCT Announces 2017 Late-breaking Clinical Trial Presentations


Related Content

News | Embolic Protection Devices

January 11, 2023 — In recent years, transcatheter mitral valve replacement (TMVR) treatment and technology has evolved ...

Home January 11, 2023
Home
News | Embolic Protection Devices

September 17, 2022 — Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial ...

Home September 17, 2022
Home
News | Embolic Protection Devices

February 9, 2021 — InspireMD Inc., developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke ...

Home February 09, 2021
Home
News | Embolic Protection Devices

August 6, 2019 — Cardiovascular Systems Inc. (CSI) has acquired the Wirion Embolic Protection System and related assets ...

Home August 06, 2019
Home
News | Embolic Protection Devices

July 19, 2019 — Medical device startup company Filterlex Medical recently completed a series A financing round, raising ...

Home July 19, 2019
Home
News | Embolic Protection Devices

August 3, 2018 — Boston Scientific Corp. announced it has recently closed its acquisition of Claret Medical Inc., a ...

Home August 03, 2018
Home
News | Embolic Protection Devices

July 20, 2018 — Boston Scientific Corp. today has signed an agreement to acquire Claret Medical Inc., which has ...

Home July 20, 2018
Home
News | Embolic Protection Devices

June 7, 2018 — The first clinical cases have been completed where the Emboliner Embolic Protection Catheter was used ...

Home June 07, 2018
Home
News | Embolic Protection Devices

May 8, 2018 — One-year results from the Sentinel Cerebral Protection System show it can reduce the incidence of stroke ...

Home May 08, 2018
Home
News | Embolic Protection Devices

April 20, 2018 — Emerging medical device company Emboline Inc. announced it has completed a Series B funding round ...

Home April 20, 2018
Home
Subscribe Now